PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33442459-4	2020	CASE SUMMARY: We present the cases of six liver transplant recipients who had previous treatment failure with sofosbuvir-based DAA therapy prior to transplantation and who then received SOF/VEL/VOX after transplant.	Sofosbuvir	110-120	small integral membrane protein 1 (Vel blood group)	Homo sapiens	186-197	
34957030-3	2021	Sofosbuvir/velpatasvir (SOF/VEL) and sofosbuvir/ledipasvir (SOF/LDV) regimens became reimbursable in China in 2020.	Sofosbuvir	0-10	small integral membrane protein 1 (Vel blood group)	Homo sapiens	24-31	
32656649-3	2020	Here, we report three patients with HCV NS5A-P32del infection who were treated with sofosbuvir, velpatasvir plus ribavirin (SOF/VEL + RBV) in a real-world setting.	Sofosbuvir	84-94	small integral membrane protein 1 (Vel blood group)	Homo sapiens	128-131	
32189931-1	2020	Background: Our data is one of the earliest study from the Indian subcontinent on Velpatasvir/Sofosbuvir (VEL/SOF) combination in chronic hepatitis C (CHC).	Sofosbuvir	94-104	small integral membrane protein 1 (Vel blood group)	Homo sapiens	106-113	
32154326-1	2020	Background: Clinical trials show high efficacy of sofosbuvir/velpatasvir (SOF/VEL), but there are limited data from "real-world" settings.	Sofosbuvir	50-60	small integral membrane protein 1 (Vel blood group)	Homo sapiens	78-81	
31433303-1	2019	BACKGROUND AND AIMS: Sofosbuvir/Velpatasivr/Voxilaprevir (SOF/VEL/VOX) is approved for retreatment of hepatitis C (HCV) patients with a previous failure to direct-acting antivirals (DAA), however real-life data are limited.	Sofosbuvir	21-31	small integral membrane protein 1 (Vel blood group)	Homo sapiens	62-65	
31012179-1	2019	Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) provides a needed hepatitis C virus (HCV) antiviral option for direct-acting antiviral (DAA)-experienced patients.	Sofosbuvir	0-10	small integral membrane protein 1 (Vel blood group)	Homo sapiens	41-44	
31203153-19	2019	LAY SUMMARY: Treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks is the current recommendation for the 5% of patients infected with HCV who do not achieve eradication of the virus under treatment with direct-acting antivirals.	Sofosbuvir	28-38	small integral membrane protein 1 (Vel blood group)	Homo sapiens	65-76	
29886154-1	2018	BACKGROUND & AIMS: Sofosbuvir, an NS5B inhibitor, combined with velpatasvir, an NS5A inhibitor (SOF/VEL), produces high sustained virologic response rates 12 weeks after treatment (SVR12) in patients with genotype 1-6 HCV infection, and has no anticipated clinically relevant drug-drug interactions with immunosuppressants.	Sofosbuvir	23-33	small integral membrane protein 1 (Vel blood group)	Homo sapiens	104-107	
30098373-14	2018	LAY SUMMARY: In phase III studies, 12 weeks of treatment with the combination of sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) cured 97% of patients with hepatitis C virus who failed prior treatment with direct-acting antiviral drugs.	Sofosbuvir	81-91	small integral membrane protein 1 (Vel blood group)	Homo sapiens	127-130	
30556034-2	2018	Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is currently approved for treatment of HCV in patients with prior treatment with DAAs.	Sofosbuvir	0-10	small integral membrane protein 1 (Vel blood group)	Homo sapiens	41-44	
30288771-4	2018	RESULTS: SOF/VEL/VOX is positioned as a salvage regimen for patients previously treated with NS5A inhibitors and for genotype 1a- and 3-infected patients who had failed other sofosbuvir-containing regimens.	Sofosbuvir	175-185	small integral membrane protein 1 (Vel blood group)	Homo sapiens	9-20	
29665069-1	2018	BACKGROUND: Data are limited regarding the effectiveness and safety of generic velpatasvir plus sofosbuvir (VEL/SOF) for hepatitis C virus (HCV) in patients with or without human immunodeficiency virus (HIV) coinfection.	Sofosbuvir	96-106	small integral membrane protein 1 (Vel blood group)	Homo sapiens	108-111